Neoadjuvant treatment with fluorouracil, leucovorin, and oxaliplatin proved to be as effective as pelvic chemoradiation with fewer adverse effects in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery.
CHICAGO — Most patients with intermediate-risk rectal cancer can undergo curative-intent treatment without the need for pelvic radiation, according to study results presented during a press conference at ASCO Annual Meeting.“Why is this a big deal? It’s a big deal because we have been radiating pelvises to treat this type of rectal cancer for the past 30 years,” Deborah
For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.